The main customers benefiting from our biomarker discovery and validation services are as follows:
OGeS has ongoing work with AstraZeneca to discover novel biomarkers for prostate cancer. Oxford Genome Sciences is using its 2D gel based proteomics platform for biomarker discovery and validation to support Astra Zeneca’s clinical development programs in oncology.
OGeS has entered into a collaboration with Bayer HealthCare AG Diagnostics Division, a member of the Bayer Group. OGeS applies its highly innovative proteomics platform, in conjunction with its OGAP®, to evaluate novel candidate biomarkers that may have important applications in clinical care for the diagnosis and prognostic assessment of breast cancer.
OGeS is collaborating with the Food and Drug Administration to discover novel biomarkers in the area of drug safety and planning to establish an extended partnership to include a pharmaceutical company sponsor.
